Showing 161-170 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Implementing Best Practice Advisories to Reduce Inequities in Technology Use for people with Type 1 Diabetes | T1D Exchange, Inc. | Nicole Rioles | Improving Lives | 01-May-2024 to 30-April-2027 | $1.995.534,06 |
| Harnessing insulin signaling in β-cells to counter type 1 diabetes | Joslin Diabetes Center Inc. | Namrata Shukla | Cures | 01-March-2024 to 28-February-2027 | $228.995,00 |
| Antigen-specific immunotherapies based on ignored ß-cell antigen determinants. | The Regents of the University of California, Los Angeles | Daniel Kaufman | Cures | 01-October-2024 to 30-September-2026 | $573.101,00 |
| Bringing Beta Cell Regenerative Therapy to the Clinic | Icahn School of Medicine at Mount Sinai | Andrew Stewart | Cures | 01-January-2024 to 31-December-2026 | $1.000.000,00 |
| Mechanisms of parathyroid protection of transplanted islets | The Regents of the University of California, San Francisco | Peng Xiao | Cures | 01-March-2024 to 28-February-2027 | $228.995,00 |
| Structural approaches to understand biased insulin signaling and design glucose-binding proteins for smart insulin therapeutics | University of Utah | Amber Vogel | Improving Lives | 01-March-2024 to 28-February-2027 | $228.995,00 |
| Treating Type 1 Diabetes: Role of Kisspeptin | Rutgers Biomedical and Health Sciences | Moshmi Bhattacharya | Cures | 01-April-2024 to 31-March-2026 | $140.000,00 |
| Defining the role of islet-derived extracellular vesicle PD-L1 cargo in type-1 diabetes | Trustees of Indiana University | Chaitra Rao | Cures | 01-March-2024 to 30-April-2027 | $228.537,45 |
| Leveraging Real-Time Insulin Sensitivity Estimation for the Adaptation of a Fully-Closed Loop Automated Insulin Delivery System to Improve Glycemic Control in Adolescents with Type 1 Diabetes | Rector & Visitors of the University of Virginia | H. Marcela Moscoso Vasquez | Improving Lives | 01-April-2024 to 31-March-2026 | $189.709,00 |
| Bcl6 and the B/Tfh axis in type 1 diabetes pathogenesis | Vanderbilt University Medical Center (VUMC) | Dudley McNitt | Cures | 01-March-2024 to 28-February-2027 | $265.320,00 |